Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
DJ Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
By Micah Maidenberg
Enzo Biochem Inc. said it hired an investment bank to evaluate various strategic options as its chief executive plans to step down from the job.
The company focused on molecular diagnostics said founder and CEO Dr. Elazar Rabbani will step down as its top leader but remain a director on the board and take a scientific role when Enzo hires a successor.
Enzo also said it retained health care investment bank Cain Brothers to "evaluate and execute strategic and commercial opportunities."
Shares rose 50% to $4.44 in after-hours trading.
For its latest quarter, Enzo reported net income of $2.3 million, or 5 cents a share, compared with a loss of $7.7 million, or 16 cents a share, for the year-earlier period. Revenue grew to $31.5 million from $19.4 million.
Increased business activity tied to the Covid-19 pandemic helped the company boost revenue, Enzo said. The company has said it provides Covid-19 molecular tests on its Genflex device.
Enzo also said that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to its board of directors.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
March 15, 2021 16:36 ET (20:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
DJ Enzo Biochem股价上涨50%，首席执行官下台；第二季度收入上升
By Micah Maidenberg
米卡·梅登伯格(Micah Madenberg)著
Enzo Biochem Inc. said it hired an investment bank to evaluate various strategic options as its chief executive plans to step down from the job.
恩佐生物化工公司(Enzo Biochem Inc.)说，在首席执行长计划辞职之际，该公司聘请了一家投资银行来评估各种战略选择。
The company focused on molecular diagnostics said founder and CEO Dr. Elazar Rabbani will step down as its top leader but remain a director on the board and take a scientific role when Enzo hires a successor.
这家专注于分子诊断的公司表示，创始人兼首席执行官埃拉扎尔·拉巴尼(Elazar Rabbani)博士将辞去最高领导人一职，但仍将担任董事会董事，在恩佐聘请继任者时担任科学角色。
Enzo also said it retained health care investment bank Cain Brothers to "evaluate and execute strategic and commercial opportunities."
恩佐还表示，它聘请了医疗保健投资银行凯恩兄弟(Cain Brothers)“评估和执行战略和商业机会。”
Shares rose 50% to $4.44 in after-hours trading.
股价在盘后交易中上涨50%，报4.44美元。
For its latest quarter, Enzo reported net income of $2.3 million, or 5 cents a share, compared with a loss of $7.7 million, or 16 cents a share, for the year-earlier period. Revenue grew to $31.5 million from $19.4 million.
恩佐最近一个季度的净收益为230万美元，合每股5美分，而去年同期为亏损770万美元，合每股亏损16美分。收入从1940万美元增长到3150万美元。
Increased business activity tied to the Covid-19 pandemic helped the company boost revenue, Enzo said. The company has said it provides Covid-19 molecular tests on its Genflex device.
恩佐说，与新冠肺炎疫情相关的商业活动增加帮助该公司增加了收入。该公司表示，它在其Genflex设备上提供新冠肺炎分子测试。
Enzo also said that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to its board of directors.
恩佐还表示，LabCorp Diagnostics前首席执行官加里·赫夫(Gary Huff)将担任董事会的战略顾问。
Write to Micah Maidenberg at micah.maidenberg@wsj.com
写信给Micah Madenberg，电子邮件：micah.madenberg@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 15, 2021 16:36 ET (20:36 GMT)
2021年3月15日美国东部时间16：36(格林尼治标准时间20：36)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧